KPMG-a business solutions, audit, tax, and advisory professional services firm-released its 2018 CEO Outlook. The report found that CEOs at large life sciences companies anticipate quickly recovering investments in digital transformation and artificial intelligence (AI), while those in the U.S. expect, or have accomplished, quicker returns than their global peers.
Among the U.S. CEOs surveyed this year, 25% said they have already achieved significant returns from AI investments and also digital transformation programs that have reshaped business functions such as product development, finance, IT, human resources, regulatory compliance, and marketing. Only 9% of global life sciences CEOs said they’ve already achieved a significant return on investment in AI and digital transformation programs.
Another 33% of CEOs surveyed-globally and in the U.S.-expect their investments in digital transformation to pay off within 12 months, the survey found.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.